Overview

Intraoperative Lidocaine Infusion as a Sole Analgesic Versus Morphine in Laparoscopic Gastric Bypass Surgery

Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
0
Participant gender:
All
Summary
Postoperative opioid-centric pain management strategies in obese patients are accompanied by the possible development of; opioid-induced ventilatory impairment (OIVI) and hypoxemia. This presents as sedation and respiratory depression, combined with upper airway obstruction and hypercapnia. If it remains undetected and untreated, it can result in increased perioperative morbidity and mortality.Thus, an increased interest in the use of non-opioid analgesic adjuncts has been prompted. Intra-operative intravenous lidocaine infusion has analgesic, anti-inflammatory, anti-hyperalgesic, opioid-sparing effects with an enhanced recovery after surgery (ERAS) profile. Its postoperative analgesia may last after reduction of its plasma concentration. So, lidocaine could be a good alternative in bariatric surgery. Lidocaine has been studied as part of an opioid-free multimodal analgesia in morbidly obese patients. Also, its use in bariatric surgery showed a decrease in postoperative opioid use and improvement in the quality of recovery.
Phase:
Early Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ain Shams University
Treatments:
Lidocaine
Morphine
Criteria
Inclusion Criteria:

- ASA physical status I- II

- body mass index (BMI) ˃ 35

- scheduled to undergo laparoscopic gastric bypass

Exclusion Criteria:

- Patients' refusal

- hypersensitivity to the study medications

- patients with known history of; hepatic disease, renal dysfunction

- severe renal impairment (eGFR <30ml/min/1.73m2)

- heart failure; left ventricular ejection fraction than 35%

- any cardiac dysrhythmias; Adam-Stokes syndrome; Wolff- Parkinson-White syndrome,
atrio-ventricular block with heart rate below 50 bpm

- chronic pain

- concomitantly taking beta blocking drugs •substance abuse disorder

- chronic opioid use.